Garg Pushkal — SEC Form 4 filings
SEC reporting owner CIK 1829252. 19 Form 4 filings on record with FilingPulse; latest filed 2026-03-06.
Transaction summary — filings shown
Covers all 19 filings on record, filed 2024-02-20 to 2026-03-06. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 159 legs across 17 filings — 101,772 shares, $30,542,189 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 28.
- Largest priced transaction: sale of 52,592 shares @ $285.00 ($14,988,720) in ALNYLAM PHARMACEUTICALS, INC., filed 2025-01-29.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP Chief R&D | 19 | — | 159 legs · 101,772 sh · $30,542,189 | 28 |
Form 4 filings — Garg Pushkal
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-03-06 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Sale (S): 106 @ $319.03 · Sale (S): 102 @ $320.01 · Sale (S): 215 @ $320.81 · Sale (S): 289 @ $321.82 · Sale (S): 350 @ $323.01 · Sale (S): 767 @ $323.84 · +6 more | EDGAR |
| 2026-03-04 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 4,769 @ $0 · Sale (S): 50 @ $323.62 · Sale (S): 97 @ $324.65 · Sale (S): 277 @ $325.63 · Sale (S): 421 @ $326.81 · Sale (S): 353 @ $327.67 · +10 more | EDGAR |
| 2026-03-02 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 1,908 @ $0 · Sale (S): 127 @ $328.92 · Sale (S): 2,259 @ $330.73 · Sale (S): 1,159 @ $331.49 · Sale (S): 942 @ $332.48 · Sale (S): 140 @ $334.39 · +1 more | EDGAR |
| 2026-02-17 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 4,579 @ $0 · Sale (S): 2,242 @ $310.08 | EDGAR |
| 2026-01-14 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 3,800 @ $0 · Sale (S): 39 @ $353.95 · Sale (S): 42 @ $355.16 · Sale (S): 41 @ $356.09 · Sale (S): 96 @ $357.17 · Sale (S): 123 @ $358.18 · +16 more | EDGAR |
| 2025-10-03 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 3,108 @ $0 · Grant/award (A): 2,851 @ $0 · Sale (S): 115 @ $446.53 · Sale (S): 56 @ $447.92 · Sale (S): 180 @ $448.77 · Sale (S): 249 @ $449.79 · +13 more | EDGAR |
| 2025-08-19 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 2,851 @ $0 · Sale (S): 39 @ $447.98 · Sale (S): 90 @ $449.92 · Sale (S): 39 @ $450.92 · Sale (S): 103 @ $451.99 · Sale (S): 329 @ $452.96 · +9 more | EDGAR |
| 2025-03-25 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Sale (S): 4,321 @ $285 · Option exercise (M): 5,445 @ $42.22 · Sale (S): 5,445 @ $300 · Option exercise (M): 5,445 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 14,137 @ $0 · Sale (S): 213 @ $242.37 · Sale (S): 235 @ $243.36 · Sale (S): 158 @ $244.41 · Sale (S): 116 @ $245.26 · Sale (S): 48 @ $246.18 · +10 more | EDGAR |
| 2025-03-03 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 1,908 @ $0 · Sale (S): 51 @ $236.51 · Sale (S): 40 @ $238.33 · Sale (S): 41 @ $239.18 · Sale (S): 91 @ $240.32 · Sale (S): 149 @ $241.51 · +4 more | EDGAR |
| 2025-02-18 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 3,109 @ $0 · Sale (S): 349 @ $252.50 · Sale (S): 386 @ $253.37 · Sale (S): 258 @ $254.35 · Sale (S): 110 @ $255.56 · Sale (S): 126 @ $256.29 · +13 more | EDGAR |
| 2025-01-29 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 23,876 @ $88.95 · Option exercise (M): 25,000 @ $88.95 · Sale (S): 52,592 @ $285 · Option exercise (M): 25,000 (derivative) @ $0 · Option exercise (M): 23,876 (derivative) @ $0 | EDGAR |
| 2024-12-13 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Sale (S): 121 @ $247.48 · Sale (S): 186 @ $248.99 · Sale (S): 426 @ $250.08 · Sale (S): 778 @ $251.68 · Sale (S): 100 @ $252.94 · Sale (S): 140 @ $254.37 · +1 more | EDGAR |
| 2024-11-27 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 3,434 @ $0 · Sale (S): 30 @ $247.77 · Sale (S): 246 @ $249.60 · Sale (S): 364 @ $250.68 · Sale (S): 945 @ $251.42 · Sale (S): 97 @ $252.27 | EDGAR |
| 2024-10-10 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 96 @ $0 | EDGAR |
| 2024-06-26 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 4,295 @ $0 · Sale (S): 78 @ $221.71 · Sale (S): 17 @ $224.17 · Sale (S): 24 @ $225.55 · Sale (S): 45 @ $226.82 · Sale (S): 169 @ $228.30 · +7 more | EDGAR |
| 2024-03-05 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 4,751 @ $0 · Grant/award (A): 9,279 (derivative) @ $0 | EDGAR |
| 2024-02-29 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 1,908 @ $0 · Sale (S): 247 @ $154.54 · Sale (S): 194 @ $155.45 · Sale (S): 115 @ $156.38 · Sale (S): 17 @ $157.30 · Sale (S): 1 @ $158.09 · +1 more | EDGAR |
| 2024-02-20 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 4,295 @ $0 · Sale (S): 480 @ $147.50 · Sale (S): 672 @ $148.24 · Sale (S): 156 @ $149.03 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1829252 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →